Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.

Arthritis Res Ther · 2019 · PMC6883678 · PMID 31783773

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.1400

boldest claim

The sentences

borderline significantP = 0.08so close (0.05 < p ≤ 0.1)

Further, the association between CZP level ≥ 20 mg/L and DAS28 improvement at 6 months was borderline significant ( β = 0.8 (95% CI − 0.1–1.8), P = 0.08).

also in 11,409 other papers

did not reach statistical significanceP = 0.14not close (p > 0.1)

In PsA patients, there was a trend for CZP level ≥ 20 mg/L to be associated with greater improvement in DAS28 at 3 and 6 months; however, it did not reach statistical significance ( β = 0.5 (95% CI − 0.2–1.3), P = 0.14, and β = 0.4 (95% CI − 0.3–1.1), P = 0.28).

also in 111,027 other papers

a slight trendno p-value reported

While there is a slight trend towards more infections with higher drug levels, the differences were not statistically significant.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.